PharmaCyte Biotech Inc (PMCB)

[Daphnis]

////////////////////////////////
PMCB: END GAME: VALUE
////////////////////////////////
•Company Buyout Evaluation
•W/Success Of Pancreatic Clinical Trial
•CellInABox Primary Function Can Treat
•Multiple Cancers
•Diabetes
•Other Ailments
•Includes A Well Protected 20yr Patent
•Opinion >$10 A Share

////////////////////////////////
PMCB: CELL IN A BOX: TECH
////////////////////////////////
•Smuggles Engineered Cells To Cancer
•Avoids Detection Of Immune System
•Engages w/Chemo Drug At Source
•Mimics Standard Liver Drug Interaction
•Far More Efficiently
•With Less Dilution & More Precision
•One Third of Chemo Drug Needed
•Little To No Side Effects
•Reduced Treatment Time

////////////////////////////////
PMCB: EVERYDAY: IS GREEN
////////////////////////////////
•Current Price Does Not Matter
•There Are Few Insiders Because
•Companies Dont Want PMCB Success
•PMCB Tech Will Hurt Profits
•w/Risk Of Losses & No Privy Info
•Bigs Are Not Secretly Buying
•Its Just Us And Shorts
•Until The Time Is Right And PMCBs
•Technology Can Speak For Itself

////////////////////////////////
PMCB: ANYTHING CAN HAPPEN: 2021
////////////////////////////////
•FDA Approval
•Expedited clinical trial
•Trial success
•Buyout